SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB)

International Journal of Antimicrobial Agents

Volumn 33, Issue 5, 2009, Pages 479-482

  Martins, Marta ^a   Viveiros, Miguel ^a   Ramos, Jorge ^a   Couto, Isabel ^a,b   Molnar, Joseph ^c   Boeree, Martin ^d   Amaral, Leonard ^a  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^c UNIVERSITY OF SZEGED   (Hungary)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Efflux pumps; Macrophages; MDR TB; SILA compounds; XDR TB

Indexed keywords

1,3 DIMETHYL 1,3 BIS(4 FLUOROPHENYL) 1,3 BIS(3 MORPHOLINOPROPYL)DISILOXANE; 1,3 DIMETHYL 1,3 BIS(4 FLUOROPHENYL) 1,3 BIS[3 [1 (4 BUTYLPIPERAZINYL)]PROPYL]DISILOXANE; SILA 409; SILA 421; SILOXANE; UNCLASSIFIED DRUG;

ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; EX VIVO STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; CELLS, CULTURED; COLONY COUNT, MICROBIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MYCOBACTERIUM TUBERCULOSIS; PIPERAZINES; SILOXANES;

EID: 62949134547     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.10.028     Document Type: Article

References (15)

1. World Health Organization. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance, 2002-2007. Anti-tuberculosis drug resistance in the world: report No. 4. Geneva, Switzerland: WHO; 2008.
2. Direcção Geral de Saúde. Programa Nacional de Luta contra a Tuberculose. Ponto da situação epidemiológica e de desempenho. Programa Nacional de Controlo da Tuberculose. Sistema de Vigilância (SVIG-TB). Lisbon, Portugal: DGS; 2006.
3. Viveiros M., Leandro C., Rodrigues L., Almeida J., Bettencourt R., Couto I., et al. Direct application of the INNO-LiPA Rif.TB line-probe assay for rapid identification of Mycobacterium tuberculosis complex strains and detection of rifampin resistance in 360 smear-positive respiratory specimens from an area of high incidence of multidrug-resistant tuberculosis. J Clin Microbiol 43 (2005) 4880-4884
4. Raviglione M.C., and Uplekar M.W. WHO's new Stop TB Strategy. Lancet 367 (2006) 952-955
5. Ordway D., Viveiros M., Leandro C., Bettencourt R., Almeida J., Martins M., et al. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 47 (2003) 917-922
6. Martins M., Schelz Z., Martins A., Molnar J., Hajös G., Riedl Z., et al. In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis. Int J Antimicrob Agents 29 (2007) 338-340
7. Amaral L., Martins M., and Viveiros M. Phenothiazines as anti-multi-drug resistant tubercular agents. Infect Disord Drug Targets 7 (2007) 257-265
8. Martins M., Viveiros M., Kristiansen J.E., Molnar J., and Amaral L. The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo 21 (2007) 771-776
9. Fusi F., Ferrara A., Zalatnai A., Molnar J., Sgaragli G., and Saponara S. Vascular activity of two silicon compounds, ALIS 409 and ALIS 421, novel multidrug-resistance reverting agents in cancer cells. Cancer Chemother Pharmacol 61 (2008) 443-451
10. Hegyes P, Molnar J, Mucsi I, Hever A, Szabo D, Kiesig S. Substituted disiloxanes, method for the production thereof and the use thereof for reversal of multidrug resistance (MDR). PCT/DE00/04110; 2000.
11. Siddiqi S.H. BACTEC 460 TB SIRE method (1985), Becton Dickinson Microbiology Systems, Sparks, MD
12. Pfyffer G.E., Bonato D.A., Ebrahimzadeh A., Gross W., Hotaling J., Kornblum J., et al. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 37 (1999) 3179-3186
13. De Bock A, Moulard P. MGIT 960 eXtended individual Susceptibility Testing For EpiCenter V5.53 A. TB eXiST for EpiCenter V5. 53A-User's Manual V1.03. Becton Dickinson; 2008.
14. Zalatnai A., and Molnár J. Effect of SILA-409, a new organosilicon multidrug resistance modifier, on human pancreatic cancer xenografts. In Vivo 20 (2006) 137-140
15. Zhang Y. Advances in the treatment of tuberculosis. Clin Pharmacol Ther 82 (2007) 595-600